1BMY:BIT
Bristol-Myers Squibb Co
€54.28
arrow_downward
-2.50%(-1.39) 1D
Oct 2, 5:26:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
News stories
From web sources and news partners
Investing.com
·
4 hours ago
RBC Capital reiterates Bristol-Myers Squibb stock rating at Sector Perform
marketscreener.com
·
4 hours ago
Bristol-Myers Squibb Seen Beating Q3 Revenue Estimates, RBC Says
Yahoo Finance
·
5 hours ago
AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying?
Insider Monkey
·
5 hours ago
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia